

SUPPLEMENTAL PRELIMINARY AMENDMENT  
U.S. Appl. No. 10/781,841

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-28. (Cancelled).

Claim 29. (New) An isolated polypeptide selected from the group consisting of:

- (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO:34, and
- (b) a polypeptide consisting of the amino acid sequence of SEQ ID NO:34 in which one or several amino acids are deleted, substituted or added, wherein said polypeptides have cranial nerve growth activity and/or nerve regenerating activity.

Claim 30. (New) An isolated DNA sequence selected from the group consisting of:

- (a) a DNA sequence consisting of the nucleotide sequence of SEQ ID NO:35 or a sequence complementary thereto, and
- (b) a DNA sequence which hybridizes with the DNA sequence defined in (a) above under washing conditions of 0.1 x SSC/0.05% SDS at 50°C, wherein the DNA sequence is capable of expressing a polypeptide having cranial nerve growth activity and/or nerve regenerating activity.

Claim 31. (New) An expression vector comprising the DNA sequence of Claim 30.

Claim 32. (New) An isolated transformant comprising the expression vector of Claim 31.

**SUPPLEMENTAL PRELIMINARY AMENDMENT**  
**U.S. Appln. No. 10/781,841**

Claim 33. (New) A process of producing a polypeptide having cranial nerve growth activity and/or nerve regenerating activity, comprising culturing the transformant of Claim 32 under suitable conditions so as to express said polynucleotide, and recovering said polypeptide having cranial nerve growth activity and/or nerve regenerating activity.

Claim 34. (New) A recombinant protein obtained by the process of Claim 33.

Claim 35. (New) An antibody which binds to the polypeptide of Claim 29 or the recombinant protein of Claim 34.